- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06052683
A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.
A Randomized Trial Evaluating Toxicity of Stereotactic Body Radiotherapy (SBRT) and Low-dose Rate Brachytherapy (LDRB) in Localized Prostate Cancer.
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are :
- Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)?
- Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB
No randomized trial has yet compared LDRB to SBRT head to head.
Study Overview
Status
Conditions
Detailed Description
Low-dose rate brachytherapy (LDRB) using Iodine-125 seed implant is known to be an effective definitive treatment for patients with low and favourable intermediate-risk prostate cancer. Mature data from Canadian institutions reported a biochemical progression-free survival as high as 90-95% at 5-10 years for patients with low and intermediate risk disease.
Prostate Stereotactic Body Radiotherapy (SBRT) as a single modality is a promising alternative to LDRB in low and favourable intermediate-risk prostate cancer. Some studies have shown the feasibility and efficacy of SBRT with low to intermediate risk-prostate cancer with 5-7 years PSA-progression-free survival really high (89,8% to 97,1% at a median follow-up of 5-7 years) [PSA: Prostate-Specific Antigen]. No randomized trial has yet compared LDRB to SBRT head to head.
Acute urinary toxicity is not trivial: a few studies have shown correlation between late urinary toxicity and the presence of acute urinary toxicity in patients treated with LDRB. Our research hypothesis is that SBRT for low and intermediate risk will result in fewer toxicities at the genito-urinary and the gastro-intestinal levels after 3 months of treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Isabelle Thibault, MD, FRCPC
- Phone Number: 67296 418-525-4444
- Email: isabelle.thibault.med@ssss.gouv.qc.ca
Study Contact Backup
- Name: Eric Vigneault, MD, FRCPC
- Phone Number: 67296 418-525-4444
- Email: eric.vigneault.med@ssss.gouv.qc.ca
Study Locations
-
-
-
Québec, Canada, G1J 1Z4
- Recruiting
- Centre Intégré de Cancérologie, CHU de Québec-Université Laval
-
Contact:
- Isabelle Thibault, MD, FRCPC
- Phone Number: 67296 418-525-4444
- Email: isabelle.thibault.med@ssss.gouv.qc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 8 months. Patients on active surveillance with evidence of disease progression are eligible to the protocol as long as they meet the eligibility criteria and have a recent prostate biopsy (within 8 months).
- Low-risk and favourable intermediate-risk prostate cancer patients are eligible according to the following definitions:
Low-risk disease defined as: Clinical stage T1-T2a and Gleason 6 and PSA ≤ 10 ng/mL
Favourable intermediate-risk cancer defined by a single NCCN intermediate risk factor:
[NCCN : National Comprehensive Cancer Network]
- Clinical stage T2b
- PSA > 10 but ≤ 20 ng/mL
- Gleason 7 (3+4)
Lymph node evaluation by either computed tomography (CT) or magnetic resonance imaging (MRI) is optional and is left at the discretion of the treating physician.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group performance status 0-1
- Patient considered medically fit for LDR brachytherapy
- Prostate volume ≤ 60 cc, measured by Trans-Rectal UltraSound (TRUS), CT or MRI, within the last 6 months.
- International Prostate Symptom Score (IPSS) ≤ 20 (alpha blockers allowed)
- No alpha reductase inhibitors use within two weeks of randomization
- No hormonal therapy is accepted
- Patients must provide a study-specified informed consent form prior to study entry.
- Patients must be willing and able to complete the EPIC-26, IPSS and SHIM questionnaires.
[EPIC-26: Expanded Prostate Cancer Index Composite score ; SHIM: Sexual Health Inventory for Men questionnaire].
Exclusion Criteria:
- Clinical or radiological evidence of metastatic disease or nodal involvement.
- Clinical stage ≥ T2b.
- Gleason score ≥ 4 + 3.
- Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3 years.
- Prior radical surgery for carcinoma of the prostate, or prior TURP (Trans-Urethral Resection of the Prostate).
- Prior pelvic radiotherapy or prior radiotherapy that would result in overlap of radiation fields.
- Prior chemotherapy for prostate cancer, or prior chemotherapy within the last 3 years.
- Prior cryosurgery of the prostate.
- Prior or current bleeding diathesis making fiducial placement or brachytherapy procedure unsafe.
- Previous androgen deprivation therapy within 6 months of the registration.
- Bilateral hip prostheses
- Any severe active comorbidity, laboratory abnormality, psychiatric illnesses, active or uncontrolled infections, serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision). Such examples includes active inflammatory bowel disease, significant urinary symptoms,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant
Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant to a total dose of 144 Gy.
|
Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
|
Experimental: Stereotactic Body Radiation Therapy to the prostate
Stereotactic Body Radiation Therapy to the prostate using 36.25 Gy in 5 fractions.
|
Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event Evaluation according to the CTCAE version 4 to assess non-inferiority of SBRT compared to LDRB.
Time Frame: 1, 3, 6, 9, 12, 18, 24 months after end of treatment and yearly after, up to 5 years.
|
Number of toxicities events assessed
|
1, 3, 6, 9, 12, 18, 24 months after end of treatment and yearly after, up to 5 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life issues in patients with prostate cancer
Time Frame: At baseline, 3, 6, 9, 12, 18 and 24 months and then yearly after, up to 5 years.
|
Expanded Prostate Cancer Index Composite score (EPIC-26 questionnaire).
In general terms, a higher score represents a better health-related quality of life.
|
At baseline, 3, 6, 9, 12, 18 and 24 months and then yearly after, up to 5 years.
|
Urinary function
Time Frame: At baseline, 1, 3, 6. 9, 12, 18, 24 and 36 months after the procedure
|
International Prostate Symptom Score (IPSS score).
The IPSS score is made up of 7 questions related to voiding symptoms.
A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
|
At baseline, 1, 3, 6. 9, 12, 18, 24 and 36 months after the procedure
|
Absolute PSA nadir to evaluate biochemical disease free survival.
Time Frame: PSA measurement every 3 months after the procedure, during the first 3 years and then every 6 months, up to 5 years
|
PSA measurements
|
PSA measurement every 3 months after the procedure, during the first 3 years and then every 6 months, up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Isabelle Thibault, MD, FRCPC, CHU de Quebec-Universite Laval
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBRT vs LDR-BT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant
-
CHU de Quebec-Universite LavalSunnybrook Health Sciences Centre; Université de MontréalCompletedProstate CancerCanada
-
British Columbia Cancer AgencyBC Cancer FoundationRecruiting
-
British Columbia Cancer AgencyActive, not recruitingProstate CancerCanada
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network; KoelisRecruiting
-
British Columbia Cancer AgencyRecruitingOligometastatic Prostate CancerCanada